-
FULC Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Fulcrum Therapeutics (FULC)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 59.41 mm | 59.41 mm | 59.41 mm | 59.41 mm | 59.41 mm | 59.41 mm |
Cash burn (monthly) | 4.81 mm | (no burn) | 6.48 mm | 1.82 mm | 5.59 mm | 184.83 k |
Cash used (since last report) | 10.00 mm | n/a | 13.47 mm | 3.80 mm | 11.62 mm | 384.49 k |
Cash remaining | 49.42 mm | n/a | 45.94 mm | 55.62 mm | 47.79 mm | 59.03 mm |
Runway (months of cash) | 10.3 | n/a | 7.1 | 30.5 | 8.6 | 319.4 |
13F holders | Current |
---|---|
Total holders | 139 |
Opened positions | 46 |
Closed positions | 36 |
Increased positions | 31 |
Reduced positions | 35 |
13F shares | Current |
---|---|
Total value | 192.27 bn |
Total shares | 65.27 mm |
Total puts | 1.90 mm |
Total calls | 6.91 mm |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 10.23 mm | $36.52 bn |
BlackRock | 5.71 mm | $20.37 bn |
TCG Crossover Management | 5.25 mm | $18.74 bn |
TCG Crossover GP II | 5.00 mm | $16.80 mm |
Nantahala Capital Management | 4.78 mm | $17.06 bn |
Vanguard | 3.27 mm | $11.69 bn |
Third Rock Ventures III | 2.34 mm | $16.96 mm |
TRV GP Iv | 2.34 mm | $8.37 bn |
Adage Capital Partners GP, L.L.C. | 2.00 mm | $7.14 bn |
GSK GSK | 1.79 mm | $38.82 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 25 | Alan A Musso | Stock Option Common Stock | Grant | Acquire A | No | No | 4.16 | 285,000 | 1.19 mm | 285,000 |
24 Jan 25 | Sapir Alex | Stock option - Right to Buy Common Stock | Grant | Acquire A | No | No | 4.16 | 582,000 | 2.42 mm | 582,000 |
24 Jan 25 | Greg Tourangeau | Stock Option Common Stock | Grant | Acquire A | No | No | 4.16 | 76,120 | 316.66 k | 76,120 |
24 Jan 25 | Curtis Gale Oltmans | Stock Option Common Stock | Grant | Acquire A | No | No | 4.16 | 225,000 | 936.00 k | 225,000 |
12 Nov 24 | King Rachel K. | Stock Option Common Stock | Grant | Acquire A | No | No | 3.64 | 60,000 | 218.40 k | 60,000 |